.png){kind=icon}
返回
OpenMATB: A Multi-Attribute Task Battery promoting task customization, software extensibility and experiment replicability
.png){kind=icon}
OA
AI
DOI：10.3758/s13428-020-01364-w.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
OpenMATB is an open-source variant of the Multi-Attribute Task Battery (MATB) and is available under a free software license. MATB consists of a set of tasks representative of those performed in aircraft piloting. It is used, in particular, to study the effect of automation on decision-making, mental workload, and vigilance. Since the publication of MATB 20 years ago, the subject of automation has grown considerably in importance. After introducing the task battery, this article highlights three main requirements for an up-to-date implementation of MATB. First, there is a need fortask customization,to make it possible to change the values, appearance or integrated components (such as rating scales) of the tasks. Second, researchers needsoftware extensibilityto enable them to integrate specific features, such as synchronization with psychophysiological devices. Third, to achieveexperiment replicability,it is necessary that the source code and the scenario files are easily available and auditable. In the present paper, we explain how these aspects are implemented in OpenMATB by presenting the software architecture and features, while placing special emphasis on the crucial role of the plugin system and the simplicity of the format used in the script files. Finally, we present a number of general trends for the future study of automation in human factors research and ergonomics.
Keyword:
Task battery
Microworld
Aircraft piloting
Task customization
Software extensibility
Experiment replicability
期刊
IF:
3.9
论文数:
711
被引数:
3.6W
机构
引用论文
Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study.png)
BloodOAAI
BloodIF0
OAAI分享收藏Building a Joint-Service Classification Research Roadmap: Individual Differences Measurement
IF0
PREAI
分享收藏Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaBlood
OAAI
BloodIF0
OAAI分享收藏Idelalisib Plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a Phase 3 Randomized Double-Blind Placebo-Controlled StudyBlood
BloodIF0
PREAI
分享收藏
查看更多内容